Plasma Atherogenic Indexes Are Independent Predictors of Slow Coronary Flow

Abdulmecit Afsin
Department of Cardiology, Adiyaman Training and Research Hospital, Adiyaman,

Hakan Kaya (✉️ kardiyolog02@gmail.com)
Department of Cardiology, Adiyaman University Faculty of Medicine, Adiyaman,

Fethi Yavuz
Department of Cardiology, Adiyaman University Faculty of Medicine, Adiyaman,

Kader Eliz Uzel
Department of Cardiology, Adiyaman Training and Research Hospital, Adiyaman,

Nurbanu Bursa
Department of Statistics, Hacettepe University Faculty of Science, Ankara,

Yusuf Hosoglu
Department of Cardiology, Adiyaman Training and Research Hospital, Adiyaman,

Arif Suner
Department of Cardiology, Adiyaman University Faculty of Medicine, Adiyaman,

Ramazan Asoglu
Department of Cardiology, Adiyaman Training and Research Hospital, Adiyaman,

Research Article

Keywords: Coronary slow flow, frame count, atherogenic index of plasma, castelli risk indices, coronary intervention, cardiovascular risk factors, coronary artery.

Posted Date: September 23rd, 2021

DOI: https://doi.org/10.21203/rs.3.rs-887908/v1

License: ☕️ This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background

Although the pathophysiology of coronary slow flow (CSF) has not been fully elucidated, emerging data increasingly support potential role for subclinical diffuse atherosclerosis in the etiology of CSF. We aimed to investigate relationship between atherogenic indices and CSF.

Methods

130 patients with CSF diagnosed according to Thrombolysis in Myocardial Infarction (TIMI)-frame count (TFC) method and 130 controls who had normal coronary flow (NCF) were included in this retrospective study. Atherogenic indices (atherogenic index of plasma [AIP], Castelli risk indices I and II [CRI-I and II]) were calculated using conventional lipid parameters.

Results

The logistic regression analyses demonstrated that AIP (OR, 5.463; 95% confidence interval [CI], 1.357–21.991; p = 0.017) and CRI-II (OR, 1.624; 95% CI, 1.138–2.319; p = 0.008) were independent predictors of CSF. Receiver operating characteristic analysis showed that the optimal cutoff value to predict the occurrence of CSF was 0.66 for AIP (sensitivity, 59%; specificity, 73%; area under curve [AUC], 0.695; p < 0.001) and 3.27 for CRI-II (sensitivity, 60%; specificity, 79%; AUC, 0.726; p < 0.001).

Conclusions

AIP and CRI-II levels were independent predictors of CSF, suggesting that atherogenic dyslipidemia may contribute to the pathophysiology of CSF.

Introduction

Coronary slow flow (CSF) is a microvascular disorder characterized by the slow entry of radiopaque contrast agent into distal vascular structures in the presence of normal or near-normal epicardial coronary arteries during coronary angiography [1]. Although there is no clear consensus regarding the pathophysiology of CSF, diffuse atherosclerosis, inflammation, increased platelet aggregability, increased microvascular tone, microvascular and endothelial dysfunction have been suggested to contribute to its pathogenesis [2]. Multiple studies to define the demographic characteristics of patients with CSF have shown that male sex, smoking, and decreased high-density lipoprotein cholesterol (HDL-C) level are more common in these patients [3–5].
Atherogenic dyslipidemia, which comprises the concurrence of increased serum triglyceride (TG), apolipoprotein B, and small dense low-density lipoprotein cholesterol (LDL-C) levels along with decreased HDL-C level, plays a major role in the genesis of atherosclerotic plaques [6]. The atherogenic index of plasma (AIP) is a relatively novel indicator of atherogenicity calculated as $\log_{10}(TG/HDL-C)$, which has been identified as an indirect indicator of small dense LDL-C and as a strong risk factor for the development of atherosclerosis [7]. Previous studies have demonstrated that, in comparison to simple lipid parameters, the atherogenic coefficient (AC; Non-HDL-C/HDL-C) and Castelli’s risk indices I and II (total cholesterol [TC]/HDL-C and LDL-C/HDL-C, respectively) had stronger correlations with cardiovascular disease and better predictive capability for cardiovascular events [8–10].

Because emerging data increasingly support potential role for subclinical diffuse atherosclerosis in the etiology of CSF, the present study was performed to investigate the relationships of lipid profile and atherogenic indices with CSF.

**Methods**

**Study Population and design**

We retrospectively analyzed the data of 9050 patients who had undergone diagnostic coronary angiography between January 2017 and August 2020 at Adiyaman University-Affiliated Hospital, with the indications of detection of ischemia in the exercise treadmill testing or myocardial perfusion scintigraphy after admission with stable angina pectoris or unstable angina pectoris. In total, 425 patients with CSF were identified. After exclusion criteria and propensity score matching, the study group consisted of 130 patients (1.5%) with CSF who did not have significant stenosis in the left main coronary artery, the other three major coronary arteries, or their side branches above 2.0 mm on coronary angiography. 130 individuals with normal coronary flow (NCF) in coronary angiography were included in the study as a control group. Selection of the study group is summarized in Figure 1. The study was approved by the Adıyaman University Clinical Research Ethics Committee (approval number: 2021/02-10). Written informed consent was obtained from all the participants included in the study, and they were informed that participation was voluntary and they were free to withdraw from the research. The study was carried out according to the Helsinki Declaration.

Serum TC level > 200 mg/dL was regarded as indicative of dyslipidemia. Hypertension was defined as blood pressure $\geq 140/90$ mm/Hg or receiving antihypertensive treatment. Diabetes mellitus was defined as fasting blood glucose level $\geq 126$ mg/dL or known diabetes mellitus diagnosis. Smoking status was regarded as positive for current smokers and for those who had quit smoking within the past 1 year with a smoking history of $> 10$ pack-years. Patients were excluded from the study if they had a previous history of acute myocardial infarction, previous percutaneous coronary intervention or coronary artery bypass graft surgery, and/or had coronary ectasia. Patients were also excluded from the study if they had coronary artery stenosis $\geq 50\%$, cerebrovascular disease, renal failure, left ventricular systolic dysfunction (left ventricular ejection fraction [LVEF] $\leq 50$), moderate to severe valvular heart disease, congenital heart
disease, cardiomyopathies (dilated, restrictive, hypertrophic), hematological disease, thyroid dysfunction, and/or inflammatory diseases, and if they used lipid-lowering drugs or lacked complete clinical data. Demographic, clinical, and laboratory data of the participants were obtained from the medical records of our hospital.

**Coronary Angiography and TIMI Frame Count (TFC)**

All coronary angiographies were performed either from the femoral or radial access using the standard technique (Siemens Axiom Artis zee 2011; Siemens Healthcare, Erlangen, Germany). Iopromide contrast medium (Bayer Pharma AG, Berlin, Germany) was used in all patients. Images of the coronary arteries were acquired in the right and left oblique planes, as well as the cranial and caudal angles, at 15 frames per second (fps). Two cardiologists who were blinded to the patients’ demographic and clinical features assessed all angiograms to define CSF. The TIMI frame count (TFC) method developed by Gibson et al. [11] was used for quantitative measurement of coronary blood flow. The first frame was defined as the frame in which the contrast agent reached the ostium and the coronary artery was first visualized, and the last frame was defined as the frame in which the contrast agent was first visualized at the distal point. The distal bifurcation (i.e., “moustache”) of the left anterior descending artery (LAD), the distal bifurcation of the longest branch of the left circumex artery (LCX), and the level at which the first lateral branch originated from the posterolateral artery of the right coronary artery (RCA) were defined as the end points. Because the calculated TFC value for LAD was substantially higher than the RCA and LCX counts, the LAD frame count was divided by the average of the numbers obtained from LCX and RCA counts to allow standardization, producing a constant coefficient of 1.7. The corrected TFC (cTFC) for LAD was calculated by dividing the LAD TFC by 1.7.

Mean reference values of 36 ± 1 TFC for LAD, 22.2 ± 4 TFC for LCX, and 20.4 ± 3 TFC for RCA were reported for the filling of coronary arteries [11]. In the present study, patients in whom the measured TFC values were greater than or equal to two standard deviations of the mean in at least one coronary artery were considered to have CSF. The mean TFC for each patient and control participant was calculated by dividing the sum of the TFCs of LAD, LCX, and RCA by 3.

**Laboratory Examination**

Laboratory findings were collected from the hospital database. Before the angiography, blood samples were collected for complete blood count analyses, following a 12 h overnight fasting. Plasma TC, TG, LDL-C, HDL-C, fasting glucose, creatinine levels were analyzed using the Architect c8000 Chemistry System (Abbott Diagnostics, USA) commercial kits. LDL-C was calculated via direct LDL-C assays. Then, AIP was determined by the base 10 logarithm of the ratio of the TG level to HDL-C level. The other indices used in this study were calculated as follows: non-HDL-C = (TC–HDL-C), AC = (non-HDL-C/HDL-C), CRI-I = (TC/HDL-C) and CRI-II = (LDL-C/HDL-C).

Complete white blood (WBC) counts, including neutrophil and lymphocyte counts, were measured using an automated hematology analyzer CELL-DYN Ruby (Abbott Diagnostics, Abbott Park, IL, USA) and...
expressed as \( \times 1.000 \) cells/mm\(^3\). Hemoglobin and platelet count were also calculated. Neutrophil to lymphocyte ratio (NLR) was calculated by dividing the neutrophil count to the lymphocyte count, and platelet to lymphocyte ratio (PLR) was calculated as the number of platelets divided by the lymphocyte count. Transthoracic echocardiographic evaluation was performed for all patients by using Vivid 5 Pro (General Electric, Horten, Norway) brand echocardiography device. LVEF was assessed using Simpson's method [12].

**Statistical Analysis**

The sample size of the study group was determined with 0.80 power and medium effect size using power analysis in R environment (R Core Team, 2020). More than 25% of this sample size (\( n=260 \)) was included in the study because of the possibility of using nonparametric tests and can be missing values. To reduce the bias when selecting the participants to CSF and NCF groups propensity score with the nearest neighbor method and 1:1 allocation ratio was used. While calculating the score, the gender and smoking status of participants took consideration. Additionally, the propensity score was calculated for more than 20% of the sample size (305) against the probability of the sample size can decrease and 260 of them was chosen for CSF and NCF groups.

All analyses were performed using SPSS, version 23 (IBM Corp., Chicago, IL, USA) and R, version 4.0.5 (R Core Team, 2020) software. Continuous variables were presented as mean ± standard deviation or median (quartile deviation), and categorical variables were presented as numbers and percentages. Kolmogorov-Smirnov test was used to determine whether the continuous variables were distributed normally or not. Independent sample t-test or Mann–Whitney U-test was used to compare continuous variables. Categorical variables were compared within the study group using chi-squared tests. Receiver operating characteristic (ROC) curve analysis was performed to find a cut-off value for AIP and CRI-II according to Youden's J index. Multiple logistic regression analysis with forward variable selection was used to determine the predictors of CSF. Hosmer-Lemeshow test was used to evaluate model fit. The odds ratio (OR) and 95% confidence interval (CI) were calculated for each independent variable. In all analyses \( p < 0.05 \) was considered statistically significant.

**Results**

In total, 130 patients with CSF and 130 control participants with NCF were included the study. The mean ages of the two groups were 54.05 ± 9.61 years and 54.82 ± 8.78 years, respectively. Both groups showed male predominance (80% and 56%, respectively). Table 1 shows the demographic and clinical characteristics of the study population. Age, hypertension status, diabetes mellitus status, and dyslipidemia status were similar between groups. The proportion of male sex and current smokers were significantly higher in the CSF group than in the NCF group \( (p < 0.001) \). The WBC, NLR, PLR, neutrophil cell count, platelet count, LDL-C, TG, non-HDL-C, AIP, AC, CRH-I, and CRI-II values were significantly higher in the CSF group than in the control group. Furthermore, the HDL-C level and lymphocyte cell count were
significantly lower in the CSF group than in the control group. There were no statistically significant differences between the two groups in terms of other laboratory parameters, TC, and LVEF (all, p > 0.05).

The corrected LAD-TFC, LAD-TFC, LCX-TFC, RCA-TFC, and mean TFC values were significantly higher in the CSF group than in the control group (all, p < 0.001). In addition, in 73% of the patients, CSF was observed in the LAD (Table 2).

The multivariate logistic regression analyses demonstrated that AIP (OR, 5.463; 95% CI, 1.357–21.991; p = 0.017), CRI-II (OR, 1.624; 95% CI, 1.138–2.319; p = 0.008), PLR (OR, 1.004; 95% CI, 1.000–1.008; p = 0.049), current smoking (OR, 3.063; 95% CI, 1.664–5.641; p < 0.001), and male gender (OR, 3.464; 95% CI, 1.746–6.875; p < 0.001) were independent predictors of CSF (Table 3).

ROC curve analysis showed that the optimal cutoff value to predict the occurrence of CSF was 0.66 for AIP (sensitivity, 59%; specificity, 73%; area under the receiver operating characteristic curve, 0.695; p < 0.001) (Fig. 2). According to ROC analysis, the optimal cutoff value to predict the occurrence of CSF was 3.27 for CRI-II (sensitivity, 60%; specificity, 79%; area under the receiver operating characteristic curve, 0.726; p < 0.001) (Fig. 3).

**Discussion**

This study was performed to investigate the relationships of CSF with traditional lipid parameters and atherogenic indices (e.g., AIP, AC, CRI-I, and CRI-II) that have been associated with increased cardiovascular risk. Atherogenic indices were higher and HDL-C values were lower in patients with CSF, compared with the control group. AIP, CRI-II, current smoking, and male sex were found to be an independent risk factor for CSF. In addition, LDL-C and non-HDL-C values were significantly higher in the CSF group compared to the control group.

In CSF, washout of the contrast agent is prolonged in the absence of any spasm, thrombus, dissection, and any stenosis that causes significant occlusion in epicardial coronary arteries. Although the incidence of CSF in diagnostic coronary angiography is not rare, its pathogenesis has not yet been well elucidated. Various mechanisms have been proposed for its etiology, including subclinical diffuse atherosclerosis. Cin et al. [13] examined the coronary arteries of 19 patients with CSF using fractional flow reserve and intravascular ultrasonography. They noted extensive calcification and diffuse intimal thickening along the vessel walls and atheroma plaques that did not cause lumen narrowing in patients with CSF, as well as diffuse atherosclerosis in the microvascular system and epicardial coronary arteries. Pekdemir et al. [14] reported diffuse intimal thickening and calcifications along epicardial arteries during coronary angiography examinations of patients with CSF. Ding et al. [15] reported that lipoprotein-associated phospholipase A2, which plays a role in inflammation and atherosclerosis in the vessel walls, was significantly and independently associated with the presence of CSF. Considering the data obtained from these studies, it may be reasonable to conclude that diffuse coronary atherosclerosis plays a role in the etiopathogenesis of CSF.
Atherogenic dyslipidemia, which is present in metabolic syndrome, insulin resistance, type 2 diabetes mellitus, and visceral adiposity, indicates an increased risk of cardiovascular disease in these patient populations [16, 17]. High levels of TG and low HDL-C levels in plasma are typical in patients with atherogenic dyslipidemia, although LDL-C levels are normal. In addition, increases in the levels of plasma very-low-density lipoprotein and small dense LDL-C, and reduced clearance of apolipoprotein B-containing particles from plasma have been identified in patients with atherogenic dyslipidemia [18]. Compared with other LDL subfractions, small dense LDL particles are more atherogenic because they are more susceptible to oxidative stress and can pass through the subendothelial space more easily due to their small diameter. Accordingly, they can stay in circulation longer and have less affinity for LDL receptors [19]. With regard to the origin of small dense LDL formation, Berneis et al. [20] proposed that TG-rich lipoproteins (e.g., very-low-density lipoprotein 1) are converted into small dense LDL after delipidation by hepatic lipase and lipoprotein lipase enzymes. The Framingham Heart Study showed that small dense LDL level is directly correlated with serum TG level and inversely correlated with serum HDL-C level in patients with metabolic syndrome [21]. It was suggested that the TG/HDL-C ratio could be used as an indicator of LDL subfraction [22]. There is increasing evidence that both predominance and elevated levels of small dense LDL-C play important roles in the initiation and progression of atherosclerosis, as well as increased risk of cardiovascular disease [19, 23, 24]. In a recent meta-analysis of 21 studies, Liou et al. [25] reported positive associations of small dense LDL level and cholesterol content of small dense LDL with the risk of coronary heart disease. These findings are supported by an increasing body of evidence in favor of the causal link between small dense LDL and coronary heart disease. However, because the test to measure small dense LDL is complex and costly, its measurement is unlikely to be applicable in routine clinical practice [26].

AIP, calculated as log_{10} (TG/HDL-C), is regarded as an indirect indicator of small dense LDL-C [7]. Wang et al. [2] described a strong correlation between AIP and syntax score in patients with coronary heart disease. In a prospective observational study of women > 60 years old, a negative correlation between HDL-C concentration and AIP was found, but observed a positive correlation between all-cause deaths and AIP, after adjusting for age, smoking, and statin therapy [27]. AIP was significantly associated with an increased risk of coronary artery calcification progression beyond that conferred by traditional risk factors [28]. In a study conducted in 1059 patients with a history of acute coronary syndrome before the age of 35 years, the presence and severity of acute coronary syndrome were found to be independently associated with AIP; and these relationships were stronger than those of simple lipid parameters (i.e., TC, TG and LDL-C) [29]. TG/HDL-C ratio, AIP and CRI indices have predicted cardiovascular events better than traditional lipid profiles such as LDL-C and non-HDL-C [30].

To our knowledge, there have been no studies regarding the relationship between CSF and AIP. In the present study, we identified a positive correlation between AIP and TIMI frame count, which is regarded as an indicator of coronary flow reserve. The predictability of TIMI frame count by AIP supports the role of diffuse atherosclerosis in the pathophysiology of CSF. The results of the present study showed that AIP provided a reference for CSF severity. In addition, LDL-C and non-HDL-C, which are defined as the main
indicator of atherogenic particles by current guidelines, were higher in the CSF group than in the control group. However, these lipid parameters were not found as predictive variables in the regression analysis.

CRI-II (LDL-C/HDL-C ratio) represents the proportion or relationship between the atherogenic and antiatherogenic lipoproteins. CRI-II has been predictive power for cardiovascular disease [10]. CRI-II was a more precise predictor for cardiovascular events than classic lipid parameters (i.e., TC, TG and LDL-C) used independently [8, 31]. Katakami et al. [32] showed that CRI-II was useful in assessing the risk of early stage carotid atherosclerosis in type 2 diabetic patients. Fujihara et al. [33] demonstrated that CRI-II was an independent predictor of coronary artery stenosis and vulnerable coronary plaque. In a study involving 54 patients with CSF, Kalayci et al. [34] reported that TG/HDL-C ratio, CRI-I and II values were higher in the CSF group than in the control group. The authors stated that age, smoking and TG predict CSF. In the present study, CRI-II was an independent predictor of CSF which was different than Kalayci et al. [34] investigation.

CSF has been reported to be more common in young male smokers. In our study, both smoking and male sex were independent risk factors for CSF. These results are consistent with previous studies. In their cross sectional study, Sanghvi et al. [35] reported that history of tobacco use was 45.5% and male sex was 62.5% in the CSF group. Furthermore, current smoking was an independent risk factor for CSF. In another study performed by Rao V et al. [4] in an Indian population, 66% of patients were males and 68% of patients were smokers in subject with CSF. In a prospective study involving 39 patients with CSF, Arbel et al. [3] reported that current smoking was the most significant variable related to CSF. Smoking association with CSF could be explained as follows: endothelial dysfunction, impaired endothelium-dependent coronary vasodilatation, increased microvascular resistance, increased oxidized LDL, and increase in mediators leading to atherosclerosis [3, 5, 36, 37].

**Study Limitations**

This study had several limitations. First, this was a single-center, retrospective observational study with a small sample size. Because of its retrospective design, inflammatory markers related to atherosclerosis (e.g., high-sensitivity C-reactive protein, interleukin-6, and adhesion molecules) were not studied, and a more detailed evaluation of the relationship between CSF and inflammation could not be performed. Apolipoprotein B and small dense LDL-C, which reflect the total atherogenic particle load better than LDL-C, were also not measured. Unfortunately, imaging modalities (e.g., intravascular ultrasonography) could not be used, although these would have better demonstrated a potential relationship between CSF and subclinical diffuse atherosclerosis. In addition, selection bias may have occurred during selection of the control group due to the retrospective study design, and some individuals with NCF in the control group may have had undetected microvascular dysfunction.

**Conclusions**
The results of this study indicated that AIP and CR II are independent predictors of CSF, suggesting that atherogenic dyslipidemia may contribute to the pathophysiology of CSF. The results also provide additional support for the importance of lipid-lowering therapy in the management of patients with CSF. Prospective studies in larger cohorts of patients may elucidate the role of atherogenic dyslipidemia in the pathophysiology of CSF.

**Declarations**

**Ethics approval and consent to participate**

The study was performed after the approval of the Adıyaman University Clinical Research Ethics Committee (approval number: 2021/02-10). Written informed consent was obtained from all the participants included in the study, and they were informed that participation was voluntary and they were free to withdraw from the research. The study was carried out according to the Helsinki Declaration.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Acknowledgments**

None

**Funding**

No funding was obtained for this study

**Availability of data and materials**

The datasets used and analysed during the current study are available from the corresponding author upon reasonable request.

**Authors’ contributions**

AA, HK, FY and KEU collected data and designed the study. The manuscript was revised and written by AA, HK, YH, AS, RA and KEU. Statistical analyzes done by NB and RA. NB and RA prepared figures 1-3. All authors read and approved the final manuscript.
References

1. Fineschi M, Bravi A, Gori T. The "slow coronary flow" phenomenon: evidence of preserved coronary flow reserve despite increased resting microvascular resistances. Int J Cardiol. 2008;127(3):358 – 61.
2. Wang X, Nie SP. The coronary slow flow phenomenon: characteristics, mechanisms and implications. Cardiovasc Diagn Ther. 2011;1(1):37–43.
3. Arbel Y, Rind E, Banai S, et al. Prevalence and predictors of slow flow in angiographically normal coronary arteries. Clin Hemorheol Microcirc. 2012;52(1):5–14.
4. Rao V SK, Garre I. Predictors of Coronary Slow Flow Phenomenon: A Retrospective Study. Ind J Car Dis Wom 2019;4:85–91.
5. Hawkins BM, Stavrakis S, Rousan TA, Abu-Fadel M, Schechter E. Coronary slow flow—prevalence and clinical correlations. Circ J. 2012;76(4):936 – 42.
6. Manjunath CN, Rawal JR, Irani PM, Madhu K. Atherogenic dyslipidemia. Indian J Endocrinol Metab. 2013;17(6):969 – 76.
7. Dobiásová M, Frohlich J, Sedová M, Brown BG. Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography. J Lipid Res. 2011;52(3):566 – 71.
8. Bhardwaj S, Bhattacharjee J, Bhatnagar MK, Tyagi S. Atherogenic index of plasma, Castelli risk index and atherogenic coefficient- new parameters in assessing cardiovascular risk. Int J Pharm Bio Sci. 2013;3:359–64.
9. Nair D, Carrigan TP, Curtin RJ, et al. Association of total cholesterol/high-density lipoprotein cholesterol ratio with proximal coronary atherosclerosis detected by multislice computed tomography. Prev Cardiol. 2009;12(1):19–26.
10. Millán J, Pintó X, Muñoz A, et al. Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention. Vasc Health Risk Manag. 2009;5:757 – 65.
11. Gibson CM, Cannon CP, Daley WL, et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation. 1996;93(5):879 – 88.
12. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1–39.e14.
13. Cin VG, Pekdemir H, Camsari A, et al. Diffuse intimal thickening of coronary arteries in slow coronary flow. Japan Heart J 2003; 44: 907–919.
14. Pekdemir H, Cin VG, Ciçek D, et al. Slow coronary flow may be a sign of diffuse atherosclerosis. Contribution of FFR and IVUS. Acta Cardiol. 2004;59(2):127 – 33.
15. Ding YD, Pei YQ, et al. Increased plasma lipoprotein-associated phospholipase A2 levels are associated with coronary slow flow. BMC Cardiovasc Disord. 2020;20(1):248.
16. Reaven GM, Chen YD, Jeppesen J, Maheux P, Krauss RM. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J Clin Invest. 1993;92:141–146.
17. Lechner K, McKenzie AL, Kränkel N, et al. High-Risk Atherosclerosis and Metabolic Phenotype: The Roles of Ectopic Adiposity, Atherogenic Dyslipidemia, and Inflammation. Metab Syndr Relat Disord. 2020;18(4):176–185.

18. Musunuru K. Atherogenic dyslipidemia: cardiovascular risk and dietary intervention. Lipids. 2010;45(10):907 – 14.

19. Ivanova EA, Myasoedova VA, Melnichenko AA, Grechko AV, Orekhov AN. Small Dense Low-Density Lipoprotein as Biomarker for Atherosclerotic Diseases. Oxid Med Cell Longev. 2017;2017:1273042.

20. Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. J Lipid Res. 2002;43(9):1363–79.

21. Kathiresan S, Otvos JD, Sullivan LM, et al. Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation. 2006;113(1):20 – 9.

22. Moriyama K. The Association between the Triglyceride to High-density Lipoprotein Cholesterol Ratio and Low-density Lipoprotein Subclasses. Intern Med. 2020;59(21): 2661–2669.

23. Hoogeveen RC, Gaubatz JW, Sun W, et al. Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the Atherosclerosis Risk In Communities (ARIC) study. Arterioscler Thromb Vasc Biol. 2014;34(5):1069-77.

24. Lawler PR, Akinkuolie AO, Chu AY, et al. Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low-Density Lipoprotein Cholesterol. J Am Heart Assoc. 2017;6(7):e005549.

25. Liou L, Kaptoge S. Association of small, dense LDL-cholesterol concentration and lipoprotein particle characteristics with coronary heart disease: A systematic review and meta-analysis. PLoS ONE. 2020;15(11): e0241993.

26. Zhu X, Yu L, Zhou H, et al. Atherogenic index of plasma is a novel and better biomarker associated with obesity: a population-based cross-sectional study in China. Lipids Health Dis. 2018;17(1):37. doi: 10.1186/s12944-018-0686-8.

27. Bendzala M, Sabaka P, Caprnda M, et al. Atherogenic index of plasma is positively associated with the risk of all-cause death in elderly women: A 10-year follow-up. Wien Klin Wochenschr. 2017;129(21–22):793–798.

28. Won KB, Han D, Lee JH, et al. Atherogenic index of plasma and coronary artery calcification progression beyond traditional risk factors according to baseline coronary artery calcium score. Sci Rep. 2020;10:21324.

29. Cai G, Liu W, Lv S, et al. Gender-specific associations between atherogenic index of plasma and the presence and severity of acute coronary syndrome in very young adults: a hospital-based observational study. Lipids Health Dis 2019;18:99.

30. Fernández-Macías JC, Ochoa-Martínez AC, Varela-Silva, JA, Pérez-Maldonado IN. Atherogenic Index of Plasma: Novel Predictive Biomarker for Cardiovascular Illnesses. Arch Med Res. 2019;50(5):285–294.
31. Johnston N, Jernberg T, Lagerqvist B, Siegbahn A, Wallentin L. Improved identification of patients with coronary artery disease by the use of new lipid and lipoprotein biomarkers. Am J Cardiol. 2006;97(5):640-5.

32. Katakami N, Kaneto H, Osonoi T, et al. Usefulness of lipoprotein ratios in assessing carotid atherosclerosis in Japanese type 2 diabetic patients. Atherosclerosis. 2011;214(2):442 – 47.

33. Fujihara K, Suzuki H, Sato A, et al. Carotid artery plaque and LDL-to-HDL cholesterol ratio predict atherosclerotic status in coronary arteries in asymptomatic patients with type 2 diabetes mellitus. J Atheroscler Thromb. 2013;20(5):452 – 64.

34. Kalaycı B, Kalaycı S, Köktürk F. Proportional Serum Lipid Parameters in Coronary Slow Flow Phenomenon. Turkiye Klinikleri J Cardiovasc Sci. 2019;31(1):21 – 8

35. Sanghvi S, Mathur R, Baroopal A, Kumar A. Clinical, demographic, risk factor and angiographic profile of coronary slow flow phenomenon: A single centre experience. Indian Heart J. 2018;(Suppl 3):S290-S294.

36. Erbay AR, Turhan H, Senen K, et al. Documentation of slow coronary flow by the thrombolysis in myocardial infarction frame count in habitual smokers with angiographically normal coronary arteries. Heart Vessels. 2004;19(6):271-4.

37. Messner B, Bernhard D. Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis. Arterioscler Thromb Vasc Biol. 2014;34(3):509 – 15.

Tables
Table 1
Demographic and laboratory findings of the study population

| Characteristics                        | CSF (n = 130) | NCF (n = 130) | p    |
|----------------------------------------|---------------|---------------|------|
| Gender (male), n (%)                   | 104 (80%)     | 73 (56%)      | < 0.001 |
| Age (years)                            | 54.05 ± 9.61  | 54.82 ± 8.78  | 0.501 |
| Smoking, n (%)                         | 79 (61%)      | 36 (28%)      | < 0.001 |
| Hypertension, n (%)                    | 52 (40%)      | 57 (44%)      | 0.615 |
| Diabetes mellitus, n (%)               | 52 (40%)      | 37 (29%)      | 0.067 |
| Dyslipidemia, n (%)                    | 76 (59%)      | 67 (52%)      | 0.319 |
| Haemoglobin, g/dL                      | 13.9 ± 1.5    | 13.9 ± 1.6    | 0.909 |
| White blood cell count, (×10^3/µL)    | 8.67 ± 2.09   | 8.10 (1.55)   | 0.029 |
| Neutrophil cell count, (×10^3/µL)     | 5 (1.18)      | 4.67 (0.85)   | 0.006 |
| Lymphocyte cell count, (×10^3/µL)     | 2.11 ± 0.54   | 2.30 (0.47)   | 0.008 |
| NLR                                    | 2.49 (0.48)   | 1.96 (0.55)   | < 0.001 |
| Platelet (10^3/µL)                     | 277 (58.25)   | 251 (38.75)   | < 0.001 |
| Mean platelet volume (fL)              | 8.43 ± 1.34   | 8.39 (0.63)   | 0.857 |
| PLR                                    | 128.39 (32.44)| 106.18 (24.43)| < 0.001 |
| Fasting glucose, mg/dl                 | 103.50 (15.25)| 108.50 (16.13)| 0.329 |
| Creatinine, mg/dl                      | 0.80 (0.12)   | 0.78 (0.08)   | 0.080 |
| LV ejection fraction (%)               | 58.6 ± 4.1    | 57.0 ± 2.6    | 0.452 |
| Total cholesterol, mg/dl               | 201.22 ± 34.32| 197.50 (26.13)| 0.411 |
| HDL cholesterol, mg/dl                 | 38.50 (5.13)  | 46 (7.50)     | < 0.001 |
| LDL cholesterol, mg/dl                 | 130.95 ± 29.82| 121.38 ± 33.53| 0.016 |
| Triglyceride, mg/dl                    | 182.50 (58.88)| 150 (50.37)   | < 0.001 |
| Non-HDL cholesterol, mg/dl             | 162.50 ± 34.39| 151.74 ± 32.35| 0.010 |
| Atherogenic index of plazma            | 0.70 ± 0.22   | 0.53 ± 0.24   | < 0.001 |
| Castelli’s risk index I                | 5.43 ± 1.44   | 4.45 ± 0.98   | < 0.001 |
| Castelli’s risk index II               | 3.55 ± 1.13   | 2.74 ± 0.84   | < 0.001 |
| Atherogenic coefficient                | 4.43 ± 1.44   | 3.45 ± 0.98   | < 0.001 |
Atherogenic coefficient: non-HDL-C/HDL-C; Atherogenic index of plasma: log TG/HDL-C; Castelli’s risk index I: TC/HDL-C; Castelli’s risk index II: LDL-C/HDL-C; CSF: coronary slow flow; Non-HDLc: TC-HDL-C; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; LV: left ventricular; NCF: normal coronary flow; NLR: neutrophil lymphocyte ratio; PLR: platelet lymphocyte ratio.

Table 2. Thrombolysis in Myocardial Infarction (TIMI) frame counts of study population

|                  | CSF (n = 130) | NCF (n = 130) | p   |
|------------------|---------------|---------------|-----|
| TFC (frame)      |               |               |     |
| LAD              | 40 (6.5)      | 14 (2)        | <0.001 |
| Corrected LAD    | 23.53 (3.83)  | 8.24 (1.17)   | <0.001 |
| LCX              | 18 (3.5)      | 9 (1.5)       | <0.001 |
| RCA              | 20 (4.5)      | 10 (1.5)      | <0.001 |
| Mean TFC         | 26 (2.34)     | 11 (1.21)     | <0.001 |

Distribution of coronary arteries relative to slow flow

|                  |               |               |     |
| LAD, n (%)       | 95 (73%)      |               |     |
| LCX, n (%)       | 40 (31%)      |               |     |
| RCA, n (%)       | 66 (51%)      |               |     |

CSF: slow coronary flow; Cx: left circumflex coronary artery; LAD: left anterior coronary artery; TFC: Thrombolysis in Myocardial Infarction frame counting; NCF: normal coronary flow; RCA: right coronary artery;

Due to technical limitations, table 3 is only available as a download in the Supplemental Files section.

Figures
9050 subjects who were scheduled for coronary angiogram

425 patients with coronary slow flow

Excluded n=250
Coronary ectasia (n=45)
Low ejection fraction (n=35)
Coronary artery stenosis ≥50% (n=90)
Valvular heart disease (n=45)
Thyroid dysfunction (n=10)
Renal failure (n=10)
Lipid-lowering drugs (n=15)

Coronary slow flow group n=175

Propensity-Score Matching
Coronary slow flow group n=130

Figure 1

Diagram shows the selection of the study groups.
Figure 2

Receiver operating characteristics curve analysis to detect the best cut-off values of atherogenic index of plasma for differentiation between slow and normal coronary flows. AUC: area under the curve
Figure 3

Receiver operating characteristics curve analysis to detect the best cut-off values of castelli risk indice II for differentiation between slow and normal coronary flows. AUC: area under the curve

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.
• Table3.jpg